IsoDDE

IsoDDE, short for Isomorphic Labs Drug Design Engine, is a unified computational drug design system developed by Isomorphic Labs, the Alphabet subsidiary spun out of Google DeepMind in 2021. The engine was introduced in a 27 page technical report titled Accurate Predictions of Novel Biomolecular Interactions with the Isomorphic Labs Drug Design Engine, published on February 10, 2026 on the company website and deposited with a Zenodo DOI.^[1] IsoDDE extends ideas pioneered by AlphaFold 3 to a single multi task system that performs protein ligand structure prediction, antibody antigen interface modelling, binding affinity estimation, and ligandable pocket identification from amino acid sequence alone.^[1][2]

The model attracted unusual attention for two reasons. First, on a generalisation benchmark that limits each test case to less than 20 percent similarity with anything in the training set, IsoDDE more than doubled the accuracy of AlphaFold 3, lifting success rates from 23.3 percent to roughly 50 percent.^[1][8] Second, IsoDDE's binding affinity predictions matched or exceeded gold standard physics based free energy perturbation methods on the FEP+, OpenFE, and CASP16 benchmarks, while running in seconds rather than the hours required by molecular dynamics.^[1] Mohammed AlQuraishi, a computational biologist at Columbia University, described the system as "a major advance, on the scale of an AlphaFold 4," while noting that the underlying methodology was almost entirely undisclosed.^[4]

Unlike AlphaFold 2 and AlphaFold 3, which were eventually released to academic users, IsoDDE is fully proprietary.^[4][7] Isomorphic Labs maintains it as the technical foundation for its own internal drug pipeline and for its multi billion dollar research collaborations with Eli Lilly, Novartis, and Johnson and Johnson.^[7] The release intensified an ongoing debate in AI drug discovery about whether the most capable structure and affinity models will remain inside commercial laboratories or be reproduced by open source projects such as Boltz, Chai-1, and OpenFold.^[4]

Background

From AlphaFold to a unified drug design engine

Isomorphic Labs was founded in November 2021 by Demis Hassabis, who continues to serve as its chief executive while also leading Google DeepMind.^[13] The company was created to apply AlphaFold style methods to the long industrial pipeline of small molecule drug discovery, an area where structure prediction alone is rarely enough. Drug projects depend not only on knowing the shape of a protein and how a candidate molecule binds to it, but also on quantifying how tightly the molecule binds, how selectively it picks out one target from related proteins, and whether new binding pockets might exist that biology has not yet exploited.

AlphaFold 3, released in May 2024 as a joint publication with Google DeepMind, was the first model that could place a protein and a small molecule into the same prediction in one shot. It also extended the original AlphaFold framework to nucleic acids, ions, and chemical modifications, with a diffusion based generative head replacing the Evoformer module of AlphaFold 2. Its PoseBusters score of about 76 percent for protein ligand poses outperformed all previous docking tools. However, AlphaFold 3's accuracy drops sharply for targets and chemistries that differ from those in its training set, a familiar weakness for structure prediction systems that are heavily anchored to the Protein Data Bank.

IsoDDE was designed to close that generalisation gap and to fold several adjacent computational tasks into one engine. The report frames IsoDDE not as a successor model that replaces AlphaFold 3 outright but as a unified system that absorbs the structure prediction capabilities of AlphaFold 3 and surrounds them with task heads for affinity, pocket detection, and antibody modelling, all trained against benchmarks that explicitly target real drug discovery problems.^[1]

Release and reception

Isomorphic Labs published the technical report and an accompanying overview article on its website on February 10, 2026.^[1][2] The report is 27 pages long and is credited to the Isomorphic Labs team rather than a single first author.^[1] A PDF copy is hosted on Zenodo, and the company also added IsoDDE to the technology page on isomorphiclabs.com, where the engine is described as "a unified drug design engine for a new era of discovery."^[3]

Within a day, coverage appeared in Scientific American, BioPharma Trend, Analytics Drift, Clinical Laboratory International, Winbuzzer, and several specialist newsletters.^{[4][5][6][8][11]} Scientific American led with the AlQuraishi quote and framed the launch as a flashpoint for the open science debate that AlphaFold itself had triggered in 2024, when more than a thousand scientists signed a petition asking for the AlphaFold 3 source code to be released.^[4]

Isomorphic Labs did not release model weights, training code, or inference code.^[4][7] The technical report itself provided benchmark numbers and architectural sketches but withheld specific details about training data, loss functions, and the exact relationship between IsoDDE and AlphaFold 3.^[1] The company stated that different internal versions of IsoDDE incorporate different data sources, with some variants trained on private structural and assay data contributed by pharmaceutical partners.^[1]

Capabilities

The technical report describes IsoDDE as a single engine that produces several different kinds of output, with shared internal representations across tasks. Four principal capabilities are reported in detail.^[1]

Four principal capabilities

Scroll sideways for more →

A fifth implicit capability runs through the report: by sharing a backbone representation across these tasks, the engine can be queried iteratively in a drug discovery workflow, for example by predicting a pocket, generating candidate poses for a virtual screening library, ranking the resulting compounds by affinity, and then folding the same pipeline back onto antibody style modalities for targets where small molecules are insufficient.

Architecture and methodology

The technical report describes IsoDDE as a multi model system that extends AlphaFold 3's diffusion based architecture rather than discarding it. The structure prediction core handles the same broad range of biomolecules as AlphaFold 3, including proteins, nucleic acids, small molecules, ions, and chemical modifications, and produces full atom three dimensional coordinates through a generative process. On top of this core, IsoDDE adds task specific heads for affinity prediction, pocket scoring, and antibody specific modelling.^[1]

The report does not disclose layer counts, hyperparameters, training set composition, or the precise loss functions used. It states that the model was trained on a combination of public structural data, proprietary internal data, and additional supervision signals from biophysical and assay measurements, but does not quantify the relative contributions.^[1] Several commentators noted that this level of disclosure is less than was provided for AlphaFold 3, which itself was criticised for the brevity of its supplementary materials.^[4]

The engine emphasises robustness to chemistry and protein space not seen in training. The report repeatedly highlights cases where IsoDDE recovers induced fit conformations or cryptic pocket openings for systems that AlphaFold 3 modelled as rigid, suggesting that the generative diffusion process has been tuned to sample alternative protein conformations more aggressively.^[1] Isomorphic Labs has not stated whether new equivariant architectures, longer diffusion trajectories, or different conditioning strategies are responsible for this behaviour.

Generative design and virtual screening

The overview article and the technical report both stress that IsoDDE is used inside Isomorphic Labs as a screen and design platform, not just a stand alone predictor.^[1][2] In practice this means generating large libraries of candidate molecules, ranking them by predicted pose and affinity, and feeding the survivors into more expensive simulation and synthesis steps. The report includes a case study on cereblon, a well known E3 ligase used in proteolysis targeting chimera (PROTAC) drug design, in which IsoDDE recovered novel pose families that earlier docking tools had missed.^[1]

Isomorphic Labs has not published the generative chemistry component as a separate system, but the report describes IsoDDE as one of two pillars of its internal drug design stack, the other being a suite of generative molecular design models.^[1]

Benchmarks and performance

IsoDDE's release was accompanied by an unusually concentrated set of benchmark comparisons against both AlphaFold 3 and open source competitors. The report focuses on tasks where structure prediction quality directly affects drug design decisions.

Protein ligand structure prediction

The headline benchmark is Runs N' Poses, an internal generalisation benchmark designed to test prediction quality on systems whose proteins and ligands are dissimilar to anything in the training data. The benchmark partitions test cases into bins based on similarity to training data, with the hardest bin containing cases that are less than 20 percent similar by the report's similarity metric. On this hardest bin, IsoDDE achieved a success rate of roughly 50 percent compared with 23.3 percent for AlphaFold 3.^[1][12]

On the independent FoldBench benchmark, IsoDDE reported 75.99 percent accuracy on protein ligand interfaces against 64.90 percent for AlphaFold 3, and 75.58 percent on antibody antigen interfaces against 47.90 percent for AlphaFold 3.^[1]

IsoDDE versus AlphaFold 3 on key benchmarks

Scroll sideways for more →

Antibody antigen interface modelling

The antibody antigen benchmarks are particularly large jumps over both AlphaFold 3 and other open source models. On a set of 334 low similarity antibody antigen complexes, IsoDDE reached 39 percent accuracy at the strict DockQ > 0.8 high fidelity threshold, compared with 17 percent for AlphaFold 3 and 2 percent for Boltz-2.^[1] For the critical CDR H3 loop, which dominates antibody specificity and is the hardest loop to predict, IsoDDE reached backbone root mean square deviation of two angstroms or better in 70 percent of cases, compared with 58 percent for AlphaFold 3 and 43 percent for Boltz-2.^[1]

These antibody results matter because most existing antibody specific tools, including dedicated antibody loop predictors, struggle to reach high fidelity accuracy on novel antigens. IsoDDE's combination of a general purpose biomolecular core with antibody specific training signals appears to deliver substantial gains on a task that has been resistant to deep learning approaches.

Binding affinity prediction

For small molecule affinity, IsoDDE was benchmarked against the FEP+ congeneric series, the OpenFE collaborative free energy benchmark, and the binding affinity prediction task in CASP16, a blind community challenge held in 2024 and 2025. On FEP+ 4 the Pearson correlation between IsoDDE predictions and experimental affinities was 0.85, compared with 0.78 for traditional FEP+ calculations.^[1] On CASP16 the IsoDDE score was 0.75 compared with 0.65 for the next best deep learning approach.^[1]

The report emphasises that IsoDDE achieves these results without requiring an experimental crystal structure of the target protein bound to a reference ligand, a starting point that traditional FEP methods cannot operate without.^[1] This eliminates a major bottleneck in early stage drug discovery, where co crystal structures are often unavailable. IsoDDE also runs in seconds per prediction on standard accelerator hardware, while a typical FEP calculation can take hours per ligand on dedicated molecular dynamics infrastructure.^[1]

Ligandable pocket identification

The pocket detection benchmark tests whether IsoDDE can identify drug binding pockets on a target protein from amino acid sequence alone, without any input ligand or known binding site. The reported AUPRC of 0.75 substantially exceeds the AUPRC of 0.51 reported for P2Rank, a widely used pocket prediction tool.^[1] The report also describes blind retrieval of cryptic and allosteric pockets that are absent in canonical apo crystal structures, comparing the result to experimental fragment soaking campaigns that can take weeks or months in a wet laboratory.^[1]

The ability to surface pockets without prior chemical matter is significant for so called undruggable targets, where the absence of known binders has historically blocked entry into a drug discovery programme.

Comparison with peer systems

IsoDDE was released into a crowded landscape of AlphaFold inspired structure prediction systems, with several open source projects having narrowed the gap with AlphaFold 3 in 2025. Direct comparisons are complicated because IsoDDE is closed source and the reported benchmarks are largely those that Isomorphic Labs chose to publish, but a clear pattern emerges from the available numbers.

Comparison to AlphaFold 3 and major open source peers

Scroll sideways for more →

Diego del Alamo of Takeda Pharmaceuticals, quoted by Scientific American, suggested that Isomorphic's collaborations with major pharmaceutical companies likely provide it with private structural and assay data not available to open source projects, which may help explain part of the performance gap on antibody and affinity benchmarks.^[4] Gabriele Corso, one of the leads of the Boltz project, told the magazine that public datasets still offer substantial room for improvement and that IsoDDE should be seen as "a new baseline to match, but also to pass."^[4]

Comparison to physics based methods

The other major comparison class for IsoDDE is the family of physics based free energy methods that have been the gold standard in computational drug design for decades. Free energy perturbation, alchemical free energy, and related molecular dynamics methods are accurate but computationally expensive and require careful preparation, including a high quality starting structure and force field parameters for every ligand.

Scroll sideways for more →

Business and strategic context

IsoDDE is not offered as a service to outside researchers. It is the core technical platform that Isomorphic Labs uses internally and that it provides to its pharmaceutical partners under collaboration agreements. The economics of the company depend on these partnerships rather than on direct sales of model access.

Partnerships and pipeline

In January 2024, Isomorphic Labs announced two major strategic deals. Eli Lilly entered into a research collaboration that includes up to 1.7 billion United States dollars in performance based milestone payments, and Novartis entered into a similar agreement with up to 1.2 billion United States dollars in milestones.^[13] Johnson and Johnson followed with a separate collaboration whose financial terms have not been disclosed.^[13] According to the DeepCeutix briefing on the IsoDDE launch, the combined potential value of the Lilly and Novartis deals exceeds three billion United States dollars before any royalty payments on commercialised drugs.^[7]

The company's own drug pipeline included 17 programmes at the time of the IsoDDE release.^[7] Isomorphic Labs has publicly stated that its first AI designed cancer drug candidate is on track to enter a Phase 1 clinical trial by the end of 2026.^[13]

Funding and closed source positioning

Isomorphic Labs raised 600 million United States dollars in its Series A round in March 2025, led by Thrive Capital with participation from existing investor GV and Alphabet, valuing the company at approximately 2.5 billion United States dollars.^[13] By February 2026 European Biotechnology Magazine and other outlets reported that the company had raised a further 2.1 billion United States dollars in additional financing.^[9][10] Alphabet remains the largest shareholder.

The choice not to release IsoDDE was deliberate and was framed by Isomorphic Labs as necessary to protect commercially sensitive training data and pipeline programmes.^[7] In Scientific American, AlQuraishi observed that the limited disclosure left external researchers "essentially guessing about methodology,"^[4] while the DeepCeutix briefing noted that the release represents a clear departure from the partial code and weights releases of AlphaFold 2 and AlphaFold 3.^[7]

Reception

The scientific reception combined strong technical admiration with explicit concern about reproducibility and open science. Several reactions appeared within days of the February 10 release.

Mohammed AlQuraishi, of the AlQuraishi Lab at Columbia University, called IsoDDE "a major advance, on the scale of an AlphaFold 4," and added that the ability to predict drug protein interactions for molecules vastly different from training data "suggests that they must have done something pretty novel."^[4] He also said that "the problem, of course, is that we know nothing of the details."^[4]

Diego del Alamo, a computational scientist at Takeda Pharmaceuticals, suggested in Scientific American that Isomorphic Labs' private collaborations with large pharmaceutical companies likely provide it with proprietary structural and assay datasets not available to academic competitors, which may contribute to its lead on antibody and affinity benchmarks.^[4]

Gabriele Corso, one of the leads on the open source Boltz models, took an optimistic view, suggesting that publicly available data still has substantial untapped potential and that IsoDDE "should be seen as a new baseline to match, but also to pass."^[4]

In industry coverage, BioPharma Trend described IsoDDE as the first system that genuinely shifts the centre of computational drug design from physics based methods to deep learning,^[5] while Analytics Drift and Clinical Laboratory International focused on the antibody and pocket detection numbers as the most surprising results.^[6] Commentary in Nature and other journals raised the broader question of whether the next generation of biological foundation models will be available to academic researchers at all, given that the most capable systems are now being developed inside commercial laboratories with access to private data and large compute budgets.

Relationship to AlphaFold 3 and the AlphaFold lineage

IsoDDE is best understood as a parallel rather than a strict successor to AlphaFold 3. The two systems share a lineage in Google DeepMind's AlphaFold work and overlapping personnel, since Demis Hassabis leads both DeepMind and Isomorphic Labs, but they target different audiences. AlphaFold 3 was released through DeepMind's research channels with inference code and weights eventually shared for non commercial use. IsoDDE is an Isomorphic Labs product designed for industrial drug discovery and is not being released. Isomorphic Labs has avoided the AlphaFold branding deliberately, both to signal that IsoDDE is a different kind of system and to retain commercial flexibility around licensing and IP.

The "AlphaFold 4" framing in AlQuraishi's quote refers to the magnitude of the technical leap rather than to an actual unreleased DeepMind successor model.^[4] There is no public AlphaFold 4 product or paper as of the IsoDDE release. The phrase has been repeated by several outlets as shorthand for the scale of the advance, but it is not Isomorphic Labs' or Google DeepMind's own description of the system.

See also

• AlphaFold 3
• AlphaFold
• Isomorphic Labs
• Google DeepMind
• Demis Hassabis
• AI drug discovery
• Protein structure prediction

References

1. Isomorphic Labs Team. *Accurate Predictions of Novel Biomolecular Interactions with the Isomorphic Labs Drug Design Engine*. Technical Report, February 10, 2026. Available at https://storage.googleapis.com/isomorphiclabs-website-public-artifacts/isodde_technical_report.pdf ↩
2. Isomorphic Labs. "The Isomorphic Labs Drug Design Engine unlocks a new frontier beyond AlphaFold." Company article, February 10, 2026. https://www.isomorphiclabs.com/articles/the-isomorphic-labs-drug-design-engine-unlocks-a-new-frontier ↩
3. Isomorphic Labs. "A unified drug design engine for a new era of discovery." Technology page, isomorphiclabs.com/our-tech ↩
4. *Scientific American*. "'An AlphaFold 4', scientists marvel at DeepMind drug spin off's exclusive new AI." February 2026. https://www.scientificamerican.com/article/an-alphafold-4-scientists-marvel-at-deepmind-drug-spin-offs-exclusive-new-ai/ ↩
5. BioPharma Trend. "Isomorphic Labs Presents an AI Drug Design Engine That Goes Beyond AlphaFold 3." February 2026. https://www.biopharmatrend.com/news/isomorphic-labs-presents-an-ai-drug-design-engine-that-goes-beyond-alphafold-3-1493/ ↩
6. Clinical Laboratory International. "Isomorphic Labs unveils IsoDDE, a unified AI drug design engine surpassing AlphaFold 3 in biomolecular prediction." February 2026. https://clinlabint.com/isomorphic-labs-unveils-isodde-a-unified-ai-drug-design-engine-surpassing-alphafold-3-in-biomolecular-prediction/ ↩
7. DeepCeutix. "Google Just Built the Best Drug Design AI in History. You Can't Use It." Strategic Briefing, February 2026. https://deepceutix.com/insights/proprietary-ai-drug-design ↩
8. Winbuzzer. "Isomorphic Labs New AI Doubles AlphaFold 3's Accuracy in Protein Ligand Predictions." February 11, 2026. https://winbuzzer.com/2026/02/11/isomorphic-labs-ai-doubles-alphafold-3-drug-discovery-accuracy-xcxwbn/ ↩
9. European Biotechnology Magazine. "Isomorphic Labs raises 2.1 billion United States dollars for AI enabled drug discovery drive." https://european-biotechnology.com/latest-news/isomorphic-labs-raises-2-1b-for-ai-enabled-drug-discovery-drive/ ↩
10. R&D World. "Alphabet spinoff Isomorphic Labs raises 2.1 billion United States dollars in quest to solve all disease with AI based drug discovery tools." https://www.rdworldonline.com/alphabet-spinoff-isomorphic-labs-raises-2-1-billion-in-quest-to-solve-all-disease-with-ai-based-drug-discovery-tools/ ↩
11. OODA Loop. "The Isomorphic Labs Drug Design Engine unlocks a new frontier beyond AlphaFold." https://oodaloop.com/briefs/technology/the-isomorphic-labs-drug-design-engine-unlocks-a-new-frontier-beyond-alphafold/ ↩
12. ASCII News. "Isomorphic Labs IsoDDE Doubles AlphaFold 3 Accuracy on Novel Protein Ligand Structures." https://ascii.co.uk/news/article/news-20260211-453af085/isomorphic-labs-isodde-doubles-alphafold-3-accuracy-on-novel ↩
13. IntuitionLabs. "Isomorphic Labs and AlphaFold: AI Drug Discovery in Trials." https://intuitionlabs.ai/articles/isomorphic-labs-alphafold-ai-drug-discovery-trials ↩